Key result
SERCA2a gene transfer cuts end-diastolic pressure ~68% in diabetic cardiomyopathy rats, restoring systolic and diastolic function.
Why the study?
The Otsuka-Long-Evans Tokushima Fatty rat model of type II diabetes mellitus exhibits diastolic dysfunction with abnormal calcium handling and decreased SERCA2a expression, motivating investigation of SERCA2a gene transfer to restore energetic deficiency and LV function.
Does SERCA2a gene transfer improve LV mechanoenergetic function in a rat model of type II diabetic cardiomyopathy?
RCT
randomized
Does SERCA2a gene transfer improve LV mechanoenergetic function in a rat model of type II diabetic cardiomyopathy?
SERCA2a gene transfer restores systolic and diastolic function and improves energy utilization in a rat model of diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rat diabetic cardiomyopathy; does not support clinical translation without human trials.
The Otsuka-Long-Evans Tokushima Fatty rat represents a model for spontaneous non-insulin-dependent type II diabetes mellitus (DM), characterized by diastolic dysfunction and associated with abnormal calcium handling and decrease in sarcoplasmic reticulum Ca2+ -ATPase (SERCA2a) expression. The aim of this study was to examine whether SERCA2a gene transfer can restore the energetic deficiency and left ventricular (LV) function in this model. DM rats were randomized to receive adenovirus carrying either the SERCA2a gene (DM + Ad.SERCA2a) or the beta-galactosidase gene (DM + Ad.betaGal) or saline (DM + saline). LV mechanoenergetic function was measured in cross-circulated heart preparations 3 days after infection. In DM, end-systolic pressure at 0.1 ml intraballoon water (ESP0.1) was low and end-diastolic pressure at 0.1 ml intraballoon water (EDP0.1) was high (22 mm Hg), compared with non-DM (EDP0.1 12 mm Hg). In DM + Ad.SERCA2a, however, ESP0.1 was increased over 200 mm Hg and EDP(0.1) was decreased to 7 mm Hg. LV relaxation rate was fast in DM + Ad.SERCA2a, but slow in the other DM groups. There was no difference in relation between cardiac oxygen consumption per beat and systolic pressure-volume area among all groups. Finally, the oxygen cost of LV contractility in DM was about three times as high as that of normal. In DM + Ad.SERCA2a, the oxygen cost decreased to control levels, but in DM + Ad.betaGal/DM + saline it remained high. In DM failing hearts, the high oxygen cost indicates energy wasting, which contributes to the contractile dysfunction observed in diabetic cardiomyopathy. SERCA2a gene transfer transforms this inefficient energy utilization into a more efficient state and restores systolic and diastolic function to normal.
No takes yet. Share an insight, caveat, or question.
Sakata et al. (2006) conducted an RCT in type II diabetes mellitus cardiomyopathy. SERCA2a gene transfer vs. beta-galactosidase gene or saline was evaluated on Left ventricular mechanoenergetic function. SERCA2a gene transfer in a rat model of diabetic cardiomyopathy decreased end-diastolic pressure to 7 mm Hg compared to 22 mm Hg in controls, restoring systolic and diastolic function.
Synapse has enriched 10 related papers. Consider them for comparative context: